Based on the analysis of the pre-therapeutic biopsies, Drebber et al25 found that patients with a higher level of HER-2 expression showed a trend of a better DFS (P = 0.1) and a significant benefit in cancer-specific survival (P = 0.03). This evidence concerns the gene ERBB2 and cancer.